Table 4.
Future directions in TLR research.
| TLR | Molecule | Type | Clinical Trial Status | Indications | Reference |
|---|---|---|---|---|---|
| TLR3 | Poly-ICLC | Agonist | In Use | Cancer Immunotherapy | [72] |
| TLR3 | RGC100 | Agonist | Research Phase | Cancer Treatment | [73] |
| TLR3 | ARNAX | Agonist | Research Phase | Cancer Treatment | [73] |
| TLR3 | poly-IC | Agonist | Research Phase | Cancer Treatment | [73] |
| TLR3 | TL-532 | Agonist | Preclinical | Cancer Immunotherapy | [74] |
| TLR9 | Various Ligands | Agonist | Clinical Settings | Cancer Therapy, Vaccine Adjuvant | [75] |
| TLR7 | GSK2245035 | Agonist | Clinical Trial | Respiratory Allergies | [78] |
| TLR7/8 | MEDI9197 | Agonist | Clinical Trial | Solid Tumors | [79] |
| TLR9 | CYT003-QbG10 | Agonist | Clinical Trial | Allergic Bronchial Asthma | [80] |
| TLR7 | Imidazo derivatives | Antagonist | Phase I | Autoimmune, Infectious Diseases | [81] |
| TLR7 | Cholesterolized Liposomes | Agonist | Preclinical | Cancer Treatment | [82] |